Hemispheric introduced Descartes, a six-billion-parameter AI foundation model trained on more than 250,000 hours of brain activity, as the NeuroAI company emerged from stealth with $52 million in early-stage funding. Developed over six years, the model is designed to decode non-invasive brain signals and translate them into actionable clinical and research insights.
The system works with a lightweight dry EEG headset that records brain activity while a patient interacts with an app for approximately 15 minutes. Descartes then generates objective results intended to support diagnosis, treatment selection and central nervous system drug and device research. Initial applications will focus on conditions including PTSD, depression, Alzheimer’s disease, schizophrenia, anxiety and mild traumatic brain injury.
For clinicians and researchers, the platform could make brain testing more objective and personalized. Hemispheric will use the funding to expand partnerships, grow its brain data network, scale its U.S. team and pursue regulatory approval.
Image Credit: Shutterstock/duen DD
Key Themes Behind This Trend
- Neuroai Diagnostics
- Foundation models trained on large-scale brain activity datasets signal a shift toward objective, data-driven assessment for complex neurological and psychiatric conditions.
- Dry EEG Interfaces
- Lightweight non-invasive headsets create new pathways for rapid brain signal capture in clinics, research settings and eventually remote care environments.
- Personalized CNS Treatment
- AI-decoded neural patterns enable more tailored therapy selection and drug development for disorders where symptom-based evaluation has limited precision.
Where This Applies
- Digital Health
- Brain-sensing platforms expand the category beyond general wellness tracking into clinically relevant measurement, diagnosis support and care personalization.
- Biopharmaceutical Research
- Objective neural biomarkers offer pharmaceutical companies richer endpoints for central nervous system trials and more precise patient stratification.
- Medical Devices
- Regulated EEG-enabled AI systems could reshape device development around compact hardware paired with scalable software intelligence.
